MorphoSys, a biotechnology company focusing on fully human antibodies, has completed the sale of its research and diagnostic antibody segment AbD Serotec to Waltham, Mass.-based Bio-Rad Laboratories.

All assets and liabilities of the AbD Serotec segment of MorphoSys, as well as all shares of the subsidiaries MorphoSys U.K., MorphoSys AbD GmbH and MorphoSys U.S., have been transferred to Bio-Rad.

"We are delighted to have reached the closing of the transaction just a few weeks after the announcement was made. With the divestment of AbD Serotec completed, MorphoSys can devote 100% of its attention to building value in its core therapeutics business," said Jens Holstein, CFO of MorphoSys.